A history of advancing cell therapies
0
+ years
Supporting innovative cell therapies
0
+
CGT developer studies supported
0
Apheresis/cell processing center partners
0
+ million
Donors in the NMDP Registry leveraged
Partnering to save lives
We have provided the resources to develop vital cell and gene therapies for more than 60 organizations, including commercial-stage allogeneic and autologous companies. We do everything in our power to help our partners bring cures to as many patients as possible, as quickly as possible — because lives depend on them.
What’s happening at NMDP BioTherapies
FDA Grants Nationwide Children’s Hospital Researchers Safe-To-Proceed Authorization on First-In-World CAR-NK Cells Made with CRISPR/AAV
March 7, 2025
Researchers at Nationwide Children’s Hospital have received safe-to-proceed approval from the Food and Drug Administration (FDA) for Universal-Donor CD38KO CD33CAR-NK cells, to be studied in a forthcoming clinical trial. The Phase 1 trial will study the safety of the novel therapy in patients with advanced, high-risk acute myeloid leukemia (AML). About NMDP BioTherapies NMDP BioTherapies…
NMDP BioTherapies Relaunches Premium Services Supporting Autologous Cell Therapies
October 8, 2024
Return to autologous business driven by loyal cell and gene biotechnology customers seeking a comprehensive solution for improved supply chain and resource efficiencies with a white glove support model Industry-leading apheresis network support and managed logistics to enable consistent harvest and reliable delivery of autologous starting material and manufactured product MINNEAPOLIS–(BUSINESS WIRE)–NMDP BioTherapiesSM (formerly known…
NMDP BioTherapies and the NMDP BioTherapies Cord Blood Bank Alliance Introduce Optimal Cord Blood Units for Manufacture of NK Cell Therapies And Other Cord Derived Cell Therapies
July 18, 2024
Leveraging the Power of the NMDP BioTherapies Cord Blood Bank Alliance, Readily Accessible Cord Blood Units That Meet the Criteria Established in Marin, et al in Nature Medicine for Production of CAR-NK Cells MINNEAPOLIS–(BUSINESS WIRE)–NMDP BioTherapiesSM (formerly known as the Be The Match BioTherapies), a leader in cell and gene therapy development support, and the NMDP…
Get in touch
Whether your cell or gene therapy is in early-stage clinical trials or nearing commercialization, we have services to support you. We’re ready to discuss your challenges and offer solutions.